HIV

Understanding adherence patterns is the first step to combat the HIV epidemic in this population.

The trial identified HIV-1 virus characteristics to predict treatment efficacy with a specific antibody treatment using sequence-based methods.

Top news of the day from across the health care landscape.

A randomized clinical trial published by JAMA Internal Medicine found that the distribution of HIV self-tests is a useful source for increasing awareness of HIV infection, and for preventing future transmission, specifically among men having sex with men.

The injectable hormone tesamorelin was found to reduce liver fat and prevent liver fibrosis or scarring in people living with HIV, according to researchers and the National Institutes of Health and the National Institute of Allergy and Infectious Disease (NIAD).

Top news of the day from across the health care landscape.

A recent study published in CANCER indicates that for patients with both HIV and cancer, implementation of the Patient Protection and Affordable Care Act (ACA) improved insurance coverage, both in states that expanded Medicaid coverage and in states that did not.1

The discovery is the first time a new subtype of HIV-1 has been identified since 2000.

The US Food and Drug Administration (FDA) has authorized marketing of the Sentosa SQ HIV Genotyping Assay, a test that detects HIV-1 drug resistance mutations using next-generation sequencing technology.

In the studies of Biktarvy from Gilead Sciences, the treatment demonstrated high rates of virologic suppression through week 144 and was found to be well-tolerated.

Researchers at the National Institute of Health (NIH) and the Massachusetts General Hospital in Boston (MGH) found that tesamorelin reduces liver fat and prevents liver fibrosis in people living with HIV.

New study provides evidence that the use of antiretroviral therapy alters the formation or stabilization of HIV latent reservoirs.

The findings of the retrospective cohort study were presented in a poster at IDWeek 2019.

Understanding which molecules HIV needs in order to leave a cell and multiply is a crucial prerequisite for investigating how the spread can be prevented.

The funding is awarded to health departments representing 57 geographic areas to expand treatment and prevention efforts for HIV/AIDS.

Doravirine (Pifeltro, Merck) and doravirine/lamivudine/tenofovir/disoproxil fumarate (Delstrigo) were initially approved for the treatment of HIV in adults with no prior antiretroviral history.

An autopsy-based study examined long-term trends in HIV-related mortality among individuals living with the disease in New York City.

New and emerging strategies in the management of HIV

Top news of the day from across the health care landscape.

HIV-related immunosuppression may contribute to an elevated risk of cancer-related morbidity in elderly patients with the disease.

A study in the Bukoba municipality of Tanzania has suggested that scaling up HIV testing, improving linkages to HIV care, and strengthening retention of antiretroviral therapy interventions can help increase viral load suppression (VLS).

It is prudent for pharmacists to stay current with these therapies and prevention strategies, as they are well-positioned to educate and support patients in their illness.

A study by the CDC has made several findings around injection practices and sexual behaviors among HIV-positive persons who inject drugs.

Vaccine found to provide durable protection against the “death star” HIV strain, which is notably hard to fight.

Data from a pair of phase 3 trials were recently presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City.

Administered through a drug-eluting implant, islatravir demonstrated protection against HIV for up to 12 months.

The TANGO study assessed whether adults maintained viral suppression for at least 6 months after switching to the the dolutegravir/lamivudine combination.

Individuals with persistent HIV in the cells of their cerebrospinal fluid are more likely to experience neurocognitive impairment.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.